Compare GSK plc (GSK) vs UiPath Inc (PATH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs UiPath Inc — how do they compare? GSK plc trades at $52.33 (market cap $101.34B), while UiPath Inc trades at $11.43 (market cap $6.19B). The key difference: GSK plc is far larger — about 16.4× UiPath Inc's market cap, and GSK plc pays a 3.49% dividend while UiPath Inc pays none. Which is the better fit depends on your goals.
| GSK | PATH | |
|---|---|---|
Market Cap | $101.34B | $6.19B |
Sector | Health | Technology |
52-Week High | $61.18 | $19.29 |
52-Week Low | $36.20 | $9.38 |
Enterprise Value | $121.95B | $4.97B |
Dividend Yield | 3.49% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
UiPath (PATH) trades at $11.94, up 0.76% with a bullish technical outlook and strong support at $11. The company shows improving fundamentals with revenue growing from $1.43B in 2025 to projected $1.7B in 2026, while transitioning from losses to profitability. Recent earnings show mixed results with Q2 2026 expectations at $0.15 EPS. The stock trades below analyst consensus target of $13.33, representing potential upside from current levels.
PATH presents a compelling turnaround story with improving profitability and strong gross margins above 80%. Key risks include execution challenges in AI monetization and competitive pressures in enterprise automation. The 25% upside to consensus target and improving cash flow trends support a constructive outlook, though investors should monitor Q2 earnings delivery and enterprise adoption of Maestro AI capabilities.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About UiPath Inc
UiPath Inc creates an end-to-end platform that provides automation with user emulation at its core. Its platform is built to be used by employees throughout a company and to address a wide variety of use cases, from simple tasks to long-running, complex business processes. It generates revenue from the sale of licenses for its proprietary software, maintenance and support, and professional services. It generates a majority of the revenues from the US, followed by Romania and the rest of the world.
Read more on PATH →
